InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Polaryx Therapeutics, Inc.

PLYX Clue Score41
United States Fiscal year ends December CIK 0002075320
$2.00 +0.00% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $2.00 −65.28% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 2 Feb 2026. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2024Operating income−4.4Net income−30.4EPS, diluted−0.89Fiscal year 2025Operating income−7.8Net income−9.0EPS, diluted−0.20
FY2024FY2025
Operating income −4.4 −7.8
Net income −30.4 −9.0
Growth
EPS, diluted −0.89 −0.20
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2024Operating cash flow−2.6Fiscal year 2025Operating cash flow−3.9
FY2024FY2025
Operating cash flow −2.6 −3.9

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2024Cash4.6Shareholders’ equity4.7Fiscal year 2025Cash5.1Shareholders’ equity4.6
FY2024FY2025
Cash 4.6 5.1
Shareholders’ equity 4.7 4.6

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
2.8 6.3
1.5 1.6
−4.4 −7.8
Growth
−30.4 −9.0
−30.4 −9.0
Growth
Per share
−0.89 −0.20
−0.89 −0.20
Growth
34.2 45.4
34.2 45.4
Growth +32.8%

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 2 of 2 years on file.